1
|
Mullier F, Baccini V, Lippi G, Lecompte T. Clinical studies on platelet transfusion: Time to consider methodological issues related to platelet counting. Transfusion 2023; 63:2198-2200. [PMID: 37965704 DOI: 10.1111/trf.17550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 09/01/2023] [Accepted: 09/04/2023] [Indexed: 11/16/2023]
Affiliation(s)
- François Mullier
- CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Hematology Laboratory, Université catholique de Louvain, Yvoir, Belgium
- Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique (IREC), Pôle Mont, Yvoir, Belgium
| | - Véronique Baccini
- Laboratoire d'Excellence GR-Ex, Université Paris Cité INSERM, BIGR, Paris, France
- UMR_S1134, Université des Antilles, Guadeloupe, France
| | - Giuseppe Lippi
- Section of Clinical Biochemistry and School of Medicine, University Hospital of Verona, Verona, Italy
| | - Thomas Lecompte
- Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Université de Namur, Namur, Belgium
- Faculté de médecine de Nancy, Université de Lorraine, Nancy, France
| |
Collapse
|
2
|
Koehl B, Claude L, Reminy K, Tarer V, Baccini V, Romana M, Colin-Aronovicz Y, Damaraju VL, Sawyer M, Peyrard T, Etienne-Julan M, Le Van Kim C, Azouzi S, Reininger L. Erythrocyte type 1 equilibrative nucleoside transporter expression in sickle cell disease and sickle cell trait. Br J Haematol 2023; 200:812-820. [PMID: 36464247 DOI: 10.1111/bjh.18586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 10/31/2022] [Accepted: 11/21/2022] [Indexed: 12/07/2022]
Abstract
Hypoxia-mediated red blood cell (RBC) sickling is central to the pathophysiology of sickle cell disease (SCD). The signalling nucleoside adenosine is thought to play a significant role in this process. This study investigated expression of the erythrocyte type 1 equilibrative nucleoside transporter (ENT1), a key regulator of plasma adenosine, in adult patients with SCD and carriers of sickle cell trait (SCT). Relative quantitative expression analysis of erythrocyte ENT1 was carried out by Western blot and flow cytometry. Patients with SCD with steady state conditions, either with SS or SC genotype, untreated or under hydroxycarbamide (HC) treatment, exhibited a relatively high variability of erythrocyte ENT1, but with levels not significantly different from normal controls. Most strikingly, expression of erythrocyte ENT1 was found to be significantly decreased in patients with SCD undergoing painful vaso-occlusive episode and, unexpectedly, also in healthy SCT carriers. Promoting hypoxia-induced adenosine signalling, the reduced expression of erythrocyte ENT1 might contribute to the pathophysiology of SCD and to the susceptibility of SCT individuals to altitude hypoxia or exercise to exhaustion.
Collapse
Affiliation(s)
- Bérengère Koehl
- Université de Paris and Université des Antilles, INSERM, Biologie Intégrée du Globule Rouge, Paris, France
| | - Livia Claude
- Université de Paris and Université des Antilles, INSERM, Biologie Intégrée du Globule Rouge, Paris, France
| | - Karen Reminy
- Université des Antilles, Laboratoire ACTES EA3596, Pointe-à-Pitre, France
| | - Vanessa Tarer
- Unité Transversale de la Drépanocytose, Centre de Référence Maladies Rares pour la Drépanocytose aux Antilles-Guyane, CHU de Pointe-à-Pitre, Pointe-à-Pitre, France
| | - Véronique Baccini
- Université de Paris and Université des Antilles, INSERM, Biologie Intégrée du Globule Rouge, Paris, France.,Service d'Hématologie, CHU de Pointe-à-Pitre, Pointe-à-Pitre, France
| | - Marc Romana
- Université de Paris and Université des Antilles, INSERM, Biologie Intégrée du Globule Rouge, Paris, France
| | - Yves Colin-Aronovicz
- Université de Paris and Université des Antilles, INSERM, Biologie Intégrée du Globule Rouge, Paris, France
| | - Vijaya L Damaraju
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | | | - Thierry Peyrard
- Université de Paris and Université des Antilles, INSERM, Biologie Intégrée du Globule Rouge, Paris, France.,Département Centre National de Référence pour les Groupes Sanguins, Paris, France
| | - Maryse Etienne-Julan
- Unité Transversale de la Drépanocytose, Centre de Référence Maladies Rares pour la Drépanocytose aux Antilles-Guyane, CHU de Pointe-à-Pitre, Pointe-à-Pitre, France
| | - Caroline Le Van Kim
- Université de Paris and Université des Antilles, INSERM, Biologie Intégrée du Globule Rouge, Paris, France
| | - Slim Azouzi
- Université de Paris and Université des Antilles, INSERM, Biologie Intégrée du Globule Rouge, Paris, France.,Département Centre National de Référence pour les Groupes Sanguins, Paris, France
| | - Luc Reininger
- Université de Paris and Université des Antilles, INSERM, Biologie Intégrée du Globule Rouge, Paris, France
| |
Collapse
|
3
|
Claude L, Martino F, Hermand P, Chahim B, Roger P, de Bourayne M, Garnier Y, Tressieres B, Colin Y, Le Van Kim C, Romana M, Baccini V. Platelet caspase-1 and Bruton tyrosine kinase activation in patients with COVID-19 is associated with disease severity and reversed in vitro by ibrutinib. Res Pract Thromb Haemost 2022; 6:e12811. [PMID: 36514346 PMCID: PMC9732813 DOI: 10.1002/rth2.12811] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 08/22/2022] [Accepted: 09/01/2022] [Indexed: 12/13/2022] Open
Abstract
Background Severity of coronavirus disease 2019 (COVID-19) is often associated with thrombotic complications and cytokine storm leading to intensive are unit (ICU) admission. Platelets are known to be responsible for abnormal hemostasis parameters (thrombocytopenia, raised D-dimers, and prolonged prothrombin time) in other viral infections through the activation of the nucleotide-binding domain leucine repeat rich containing protein 3 inflammasome induced by signaling pathways driven by Bruton tyrosine kinase (BTK) and leading to caspase-1 activation. Objectives We hypothesized that caspase-1 activation and the phosphorylation of BTK could be associated with the severity of the disease and that ibrutinib, a BTK inhibitor, could inhibit platelet activation. Methods and Results We studied caspase-1 activation by flow cytometry and the phosphorylation of BTK by Western blot in a cohort of 51 Afro-Carribean patients with COVID-19 disease (19 not treated in ICU and 32 treated in ICU). Patients with a platelet count of 286.7 × 109/L (69-642 × 109/L) were treated by steroids and heparin preventive anticoagulation. Caspase-1 and BTK activation were associated with the severity of the disease and with the procoagulant state of the patients. Furthermore, we showed in vitro that the plasma of ICU patients with COVID-19 was able to increase CD62P expression and caspase-1 activity of healthy platelets and that ibrutinib could prevent it. Conclusions Our results show that caspase-1 and BTK activation are related to disease severity and suggest the therapeutic hope raised by ibrutinib in the treatment of COVID-19 by reducing the procoagulant state of the patients.
Collapse
Affiliation(s)
- Livia Claude
- Université des Antilles, UMR_S1134, BIGRPointe‐à‐PitreFrance,Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Frédéric Martino
- Université des Antilles, UMR_S1134, BIGRPointe‐à‐PitreFrance,Service de Réanimation, CHU de la GuadeloupePointe à PitreGuadeloupe
| | - Patricia Hermand
- Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Bassel Chahim
- Service Post‐Urgences, CHU de la GuadeloupePointe à PitreGuadeloupe
| | | | | | - Yohann Garnier
- Université des Antilles, UMR_S1134, BIGRPointe‐à‐PitreFrance,Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Benoit Tressieres
- Centre d'Investigation Clinique Antilles Guyane, Inserm CIC 1424, CHU de la GuadeloupePointe‐à‐PitreGuadeloupe
| | - Yves Colin
- Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Caroline Le Van Kim
- Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Marc Romana
- Université des Antilles, UMR_S1134, BIGRPointe‐à‐PitreFrance,Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance
| | - Véronique Baccini
- Université des Antilles, UMR_S1134, BIGRPointe‐à‐PitreFrance,Laboratoire d'Excellence GR‐ExParisFrance,Université Paris Cité, UMR_S1134, BIGR, INSERMParisFrance,Institut National de la Transfusion SanguineParisFrance,Laboratoire d'HématologieCHU de la GuadeloupePointe à PitreGuadeloupe
| |
Collapse
|
4
|
Lours C, Cottin L, Wiber M, Andrieu V, Baccini V, Baseggio L, Brouzes C, Chatelain B, Daliphard S, Fenneteau O, Geneviève F, Girard S, Leymarie V, Maloum K, Rieu JB, Sebahoun G, Sudaka I, Troussard X, Wagner-Ballon O, Wuilleme S, Bardet V, Lesesve JF. Perls’ Stain Guidelines from the French-Speaking Cellular Hematology Group (GFHC). Diagnostics (Basel) 2022; 12:diagnostics12071698. [PMID: 35885602 PMCID: PMC9318570 DOI: 10.3390/diagnostics12071698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 06/30/2022] [Accepted: 07/06/2022] [Indexed: 11/16/2022] Open
Abstract
In order to standardize cellular hematology practices, the French-speaking Cellular Hematology Group (Groupe Francophone d’Hématologie Cellulaire, GFHC) focused on Perls’ stain. A national survey was carried out, leading to the proposal of recommendations on insoluble iron detection and quantification in bone marrow. The criteria presented here met with a “strong professional agreement” and follow the suggestions of the World Health Organization’s classification of hematological malignancies.
Collapse
Affiliation(s)
- Camille Lours
- Service d’Hématologie Biologique, Centre de Biologie et de Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, 69500 Bron, France;
- Correspondence:
| | - Laurane Cottin
- Laboratoire d’Hématologie, Centre Hospitalier Universitaire d’Angers, 49100 Angers, France; (L.C.); (M.W.); (F.G.)
| | - Margaux Wiber
- Laboratoire d’Hématologie, Centre Hospitalier Universitaire d’Angers, 49100 Angers, France; (L.C.); (M.W.); (F.G.)
| | - Valérie Andrieu
- Département d’Hématologie et Immunologie, Groupement Hospitalier Bichat Claude Bernard, 75018 Paris, France;
| | - Véronique Baccini
- Laboratoire d’Hématologie Immunologie, Centre Hospitalier Universitaire de Pointe-à-Pitre, 97159 Pointe-à-Pitre, France;
| | - Lucile Baseggio
- Service d’Hématologie Biologique, Centre de Biologie et de Pathologie Sud, Hôpital Lyon Sud, Hospices Civils de Lyon, 69495 Pierre Bénite, France;
| | - Chantal Brouzes
- Service d’Hématologie Biologique, Hôpital Necker, 75015 Paris, France;
| | - Bernard Chatelain
- Laboratoire d’Hématologie, Clinique Universitaire UCL de Mont-Godinne, 5530 Yvoir, Belgium;
| | - Sylvie Daliphard
- Laboratoire d’Hématologie, Centre Hospitalier Universitaire de Rouen, 76000 Rouen, France;
| | - Odile Fenneteau
- Laboratoire d’Hématologie, Hôpital Robert Debré, 75019 Paris, France;
| | - Franck Geneviève
- Laboratoire d’Hématologie, Centre Hospitalier Universitaire d’Angers, 49100 Angers, France; (L.C.); (M.W.); (F.G.)
| | - Sandrine Girard
- Service d’Hématologie Biologique, Centre de Biologie et de Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, 69500 Bron, France;
| | - Vincent Leymarie
- Laboratoire d’Hématologie, Centre Hospitalier d’Avicenne, 93000 Bobigny, France;
| | - Karim Maloum
- Service d’Hématologie Biologique, Hôpital Pitié Salpêtrière, 75013 Paris, France;
| | - Jean-Baptiste Rieu
- Laboratoire d’Hématologie, Institut Universitaire du Cancer—Oncopôle, 31100 Toulouse, France;
| | - Gérard Sebahoun
- Laboratoire d’Hématologie, APHM Hôpital Nord, 13005 Marseille, France;
| | - Isabelle Sudaka
- Laboratoire d’Hématologie, Hôpital Pasteur, 06000 Nice, France;
| | - Xavier Troussard
- Laboratoire d’Hématologie, Centre Hospitalier Universitaire de Caen, 14033 Caen, France;
| | - Orianne Wagner-Ballon
- Département d’Hématologie et d’Immunologie Biologiques, Hôpital Universitaire Henri Mondor, 94000 Créteil, France;
| | - Soraya Wuilleme
- Laboratoire d’Hématologie, Centre Hospitalier de Nantes, 44000 Nantes, France;
| | - Valérie Bardet
- Service d’Hématologie-Immunologie-Transfusion, CHU Ambroise Paré, INSERM UMR 1184, AP-HP, Université Paris Saclay, 92100 Boulogne Billancourt, France;
| | - Jean-François Lesesve
- Laboratoire d’Hématologie, Centre Hospitalier Universitaire de Nancy, 54000 Nancy, France;
| |
Collapse
|
5
|
Romana M, Leduc M, Hermand P, Bruce J, Gautier EF, Martino F, Garnier Y, Baccini V, Le Van Kim C. Proteomic analysis of neutrophils from patients with COVID-19. Br J Haematol 2022; 199:61-64. [PMID: 35818311 PMCID: PMC9349388 DOI: 10.1111/bjh.18347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 06/21/2022] [Accepted: 06/24/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Marc Romana
- Université Paris Cité and Université des Antilles, Inserm, BIGR, Paris, France
| | - Marjorie Leduc
- 3P5 Proteom'IC facility, Université Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France
| | - Patricia Hermand
- Université Paris Cité and Université des Antilles, Inserm, BIGR, Paris, France
| | - Johanna Bruce
- 3P5 Proteom'IC facility, Université Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France
| | - Emilie-Fleur Gautier
- 3P5 Proteom'IC facility, Université Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France
| | - Frédéric Martino
- Université Paris Cité and Université des Antilles, Inserm, BIGR, Paris, France.,CHU de Pointe-à-Pitre, Guadeloupe, France
| | - Yohann Garnier
- Université Paris Cité and Université des Antilles, Inserm, BIGR, Paris, France
| | - Véronique Baccini
- Université Paris Cité and Université des Antilles, Inserm, BIGR, Paris, France.,CHU de Pointe-à-Pitre, Guadeloupe, France
| | - Caroline Le Van Kim
- Université Paris Cité and Université des Antilles, Inserm, BIGR, Paris, France
| |
Collapse
|
6
|
Lafage-Pochitaloff M, Gerby B, Baccini V, Largeaud L, Fregona V, Prade N, Juvin PY, Jamrog L, Bories P, Hébrard S, Lagarde S, Mansat-De Mas V, Dovey OM, Yusa K, Vassiliou GS, Jansen JH, Tekath T, Rombaut D, Ameye G, Barin C, Bidet A, Boudjarane J, Collonge-Rame MA, Gervais C, Ittel A, Lefebvre C, Luquet I, Michaux L, Nadal N, Poirel HA, Radford-Weiss I, Ribourtout B, Richebourg S, Struski S, Terré C, Tigaud I, Penther D, Eclache V, Fontenay M, Broccardo C, Delabesse, E. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11. Blood Adv 2022; 6:386-398. [PMID: 34638130 PMCID: PMC8791575 DOI: 10.1182/bloodadvances.2021005311] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Accepted: 08/10/2021] [Indexed: 11/24/2022] Open
Abstract
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to peripheral cytopenias and in a substantial proportion of cases to acute myeloid leukemia. The deletion of the long arm of chromosome 11, del(11q), is a rare but recurrent clonal event in MDS. Here, we detail the largest series of 113 cases of MDS and myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) harboring a del(11q) analyzed at clinical, cytological, cytogenetic, and molecular levels. Female predominance, a survival prognosis similar to other MDS, a low monocyte count, and dysmegakaryopoiesis were the specific clinical and cytological features of del(11q) MDS. In most cases, del(11q) was isolated, primary and interstitial encompassing the 11q22-23 region containing ATM, KMT2A, and CBL genes. The common deleted region at 11q23.2 is centered on an intergenic region between CADM1 (also known as Tumor Suppressor in Lung Cancer 1) and NXPE2. CADM1 was expressed in all myeloid cells analyzed in contrast to NXPE2. At the functional level, the deletion of Cadm1 in murine Lineage-Sca1+Kit+ cells modifies the lymphoid-to-myeloid ratio in bone marrow, although not altering their multilineage hematopoietic reconstitution potential after syngenic transplantation. Together with the frequent simultaneous deletions of KMT2A, ATM, and CBL and mutations of ASXL1, SF3B1, and CBL, we show that CADM1 may be important in the physiopathology of the del(11q) MDS, extending its role as tumor-suppressor gene from solid tumors to hematopoietic malignancies.
Collapse
Affiliation(s)
- Marina Lafage-Pochitaloff
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique Hématologique, Centre Hospitalier Universitaire (CHU) de Marseille, Aix-Marseille University, Marseille, France
| | - Bastien Gerby
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
| | - Véronique Baccini
- Groupe Francophone d’Hématologie Cellulaire (GFHC) and
- Laboratoire d’hématologie, CHU de Guadeloupe, Inserm Unité Mixte de Recherche 1134, Pointe à Pitre, France
| | - Laetitia Largeaud
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Laboratoire d’Hématologie, Institut Universitaire de Cancérologie de Toulouse, CHU Toulouse, France
- Department of Hematology, University Toulouse III, Toulouse, France
| | - Vincent Fregona
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
| | - Naïs Prade
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Laboratoire d’Hématologie, Institut Universitaire de Cancérologie de Toulouse, CHU Toulouse, France
| | - Pierre-Yves Juvin
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
| | - Laura Jamrog
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
| | - Pierre Bories
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
| | - Sylvie Hébrard
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
| | - Stéphanie Lagarde
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Laboratoire d’Hématologie, Institut Universitaire de Cancérologie de Toulouse, CHU Toulouse, France
| | - Véronique Mansat-De Mas
- Laboratoire d’Hématologie, Institut Universitaire de Cancérologie de Toulouse, CHU Toulouse, France
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 8, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
| | - Oliver M. Dovey
- Gene Editing, Wellcome Sanger Institute, Hinxton, Cambridge, UK
| | - Kosuke Yusa
- Stem Cell Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK
| | - George S. Vassiliou
- Wellcome Sanger Institute, Hinxton, UK
- Department of Haematology, Cambridge University Hospitals National Health Service Trust, Cambridge, UK
- Wellcome-Medical Research Council Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK
| | - Joop H. Jansen
- Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Tobias Tekath
- Institute of Medical Informatics, University of Münster, Münster, Germany
| | - David Rombaut
- Institut Cochin, Université de Paris, Inserm U1016, Centre National de la Recherche Scientifique UMR8104, Paris, France
| | - Geneviève Ameye
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Belgium Cancer Registry, Brussels, Belgium
- Department of Human Genetics, Katholieke Universiteit Leuven and Universitair Ziekenhuis, Leuven, Belgium
| | - Carole Barin
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique, CHU de Tours, France
| | - Audrey Bidet
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire d’Hématologie, CHU de Bordeaux, Bordeaux, France
| | - John Boudjarane
- Laboratoire de Cytogénétique Hématologique, Centre Hospitalier Universitaire (CHU) de Marseille, Aix-Marseille University, Marseille, France
| | - Marie-Agnès Collonge-Rame
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique, CHU de Besançon, Besançon, France
| | - Carine Gervais
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique, CHU de Strasbourg, Strasbourg, France
| | - Antoine Ittel
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Département de Biopathologie, Institut Paoli-Calmettes, Marseille, France
| | - Christine Lefebvre
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique, CHU de Grenoble, Grenoble, France
| | - Isabelle Luquet
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire d’Hématologie, Institut Universitaire de Cancérologie de Toulouse, CHU Toulouse, France
- Laboratoire de Cytogénétique, CHU de Reims, Reims, France
| | - Lucienne Michaux
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Department of Human Genetics, Katholieke Universiteit Leuven and Universitair Ziekenhuis, Leuven, Belgium
| | - Nathalie Nadal
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique, CHU de Saint-Etienne, Saint-Etienne, France
| | - Hélène A. Poirel
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Belgium Cancer Registry, Brussels, Belgium
| | - Isabelle Radford-Weiss
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique, CHU de Paris-Necker, Paris, France
| | - Bénédicte Ribourtout
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire d'Hématologie, CHU d'Angers, Angers, France
| | - Steven Richebourg
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique, CHU de Nantes, Nantes, France
| | - Stéphanie Struski
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire d’Hématologie, Institut Universitaire de Cancérologie de Toulouse, CHU Toulouse, France
| | - Christine Terré
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique, CH de Versailles, Le Chesnay, France
| | - Isabelle Tigaud
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique, CHU de Lyon, Lyon, France
| | - Dominique Penther
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire de Cytogénétique, Centre Henri-Becquerel, Rouen, France
| | - Virginie Eclache
- Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Laboratoire d’Hématologie, CHU Avicenne, Bobigny, France
- Groupe Francophone des Myélodysplasies (GFM); and
| | - Michaela Fontenay
- Institut Cochin, Université de Paris, Inserm U1016, Centre National de la Recherche Scientifique UMR8104, Paris, France
- Groupe Francophone des Myélodysplasies (GFM); and
- Laboratoire d’hématologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Paris, France
| | - Cyril Broccardo
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
| | - Eric Delabesse,
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 16, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France
- Laboratoire d’Hématologie, Institut Universitaire de Cancérologie de Toulouse, CHU Toulouse, France
| |
Collapse
|
7
|
Garnier Y, Claude L, Hermand P, Sachou E, Claes A, Desplan K, Chahim B, Roger PM, Martino F, Colin Y, Le Van Kim C, Baccini V, Romana M. Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine-dependent manner. Br J Haematol 2021; 196:1159-1169. [PMID: 34962643 DOI: 10.1111/bjh.18019] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Accepted: 12/13/2021] [Indexed: 12/15/2022]
Abstract
COVID-19 urges scientists to better describe its pathophysiology to find new therapeutic approaches. While risk factors such as ageing, obesity and diabetes mellitus suggest a central role of endothelial cells (ECs), autopsies revealed clots in the pulmonary microvasculature, which are rich in neutrophils and DNA traps produced by these cells and called NETs. Moreover, submicron extracellular vesicles called microparticles (MPs), are described in several diseases as involved in pro-inflammatory pathways. Therefore, we analyzed 3 patient groups: one for which intubation was not necessary, an intubated group, and the last one after extubating. In the most severe group, the intubated group, platelet-derived MPs and endothelial cell-derived MPs exhibited increased concentration and size, when compared to uninfected controls. MPs of intubated COVID-19 patients triggered ECs death and overexpression of two adhesion molecules: P-selectin and VCAM-1. Strikingly, neutrophils adhesion and NET production were increased following incubation with these ECs. Importantly, we also showed that preincubation of these COVID-19 MPs with the phosphatidylserine capping endogenous protein annexin A5, abolished cytotoxicity, P-selectin and VCAM-1 induction, all like increases in neutrophil adhesion and NET release. Altogether our results unveil that MPs are a key actor in COVID-19 pathophysiology and point towards a potential therapeutic: annexin A5.
Collapse
Affiliation(s)
- Yohann Garnier
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| | - Livia Claude
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| | - Patricia Hermand
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,Institut National de la Transfusion Sanguine, 75015, Paris, France
| | - Evely Sachou
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| | - Aurélie Claes
- Institut Pasteur, 75015, Paris, France.,CNRS ERL9195, 75015, Paris, France.,INSERM U1201, 75015, Paris, France
| | - Kassandra Desplan
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| | - Bassel Chahim
- Service de post-urgences, CHU Pointe à Pitre-Abymes, Pointe à Pitre, Guadeloupe, France
| | - Pierre-Marie Roger
- Service d'infectiologie CHU Pointe à Pitre-Abymes, Pointe à Pitre, Guadeloupe, France
| | - Frédéric Martino
- Service de réanimation, CHU Pointe à Pitre-Abymes, Pointe à Pitre, Guadeloupe, France
| | - Yves Colin
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,Institut National de la Transfusion Sanguine, 75015, Paris, France
| | - Caroline Le Van Kim
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,Institut National de la Transfusion Sanguine, 75015, Paris, France
| | - Véronique Baccini
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| | - Marc Romana
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| |
Collapse
|
8
|
Baccini V, Geneviève F, Jacqmin H, Chatelain B, Girard S, Wuilleme S, Vedrenne A, Guiheneuf E, Toussaint-Hacquard M, Everaere F, Soulard M, Lesesve JF, Bardet V. Platelet Counting: Ugly Traps and Good Advice. Proposals from the French-Speaking Cellular Hematology Group (GFHC). J Clin Med 2020; 9:jcm9030808. [PMID: 32188124 PMCID: PMC7141345 DOI: 10.3390/jcm9030808] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 03/12/2020] [Accepted: 03/12/2020] [Indexed: 12/25/2022] Open
Abstract
Despite the ongoing development of automated hematology analyzers to optimize complete blood count results, platelet count still suffers from pre-analytical or analytical pitfalls, including EDTA-induced pseudothrombocytopenia. Although most of these interferences are widely known, laboratory practices remain highly heterogeneous. In order to harmonize and standardize cellular hematology practices, the French-speaking Cellular Hematology Group (GFHC) wants to focus on interferences that could affect the platelet count and to detail the verification steps with minimal recommendations, taking into account the different technologies employed nowadays. The conclusions of the GFHC presented here met with a "strong professional agreement" and are explained with their rationale to define the course of actions, in case thrombocytopenia or thrombocytosis is detected. They are proposed as minimum recommendations to be used by each specialist in laboratory medicine who remains free to use more restrictive guidelines based on the patient’s condition.
Collapse
Affiliation(s)
- Véronique Baccini
- Laboratoire d’hématologie, CHU de la Guadeloupe, INSERM UMR S_1134, 97159 Pointe-à-Pitre, France
- Correspondence:
| | - Franck Geneviève
- Fédération Hospitalo-Universitaire ‘Grand Ouest Against Leukemia’ (FHU GOAL), 49033 Angers, France;
| | - Hugues Jacqmin
- Université Catholique de Louvain, CHU UCL Namur, Laboratoire d’hématologie, Namur Thrombosis and Hemostasis Center, 5530 Yvoir, Belgium; (H.J.); (B.C.)
| | - Bernard Chatelain
- Université Catholique de Louvain, CHU UCL Namur, Laboratoire d’hématologie, Namur Thrombosis and Hemostasis Center, 5530 Yvoir, Belgium; (H.J.); (B.C.)
| | - Sandrine Girard
- Hospices Civils de Lyon, Centre de biologie et pathologie Est, Service d’hématologie biologique, 69500 Bron, France;
| | - Soraya Wuilleme
- Laboratoire d’Hématologie, Institut de Biologie, CHU de Nantes; 44093 Nantes CEDEX, France;
| | - Aurélie Vedrenne
- Service de biologie clinique, Hôpital Foch, 92150 Suresnes, France;
| | - Eric Guiheneuf
- Service d’Hématologie Biologique, CHU Amiens-Picardie, 80054 Amiens CEDEX, France;
| | | | | | - Michel Soulard
- Plateau technique d’hématologie, Laboratoire Biogroup, 92300 Levallois-Perret, France;
| | | | - Valérie Bardet
- Service d’Hématologie-Immunologie-Transfusion, CHU Ambroise Paré, INSERM UMR 1184, AP-HP, Université Paris Saclay, 92100 Boulogne-Billancourt, France;
| |
Collapse
|
9
|
Ghalloussi D, Rousset-Rouvière C, Popovici C, Garaix F, Saut N, Saultier P, Tsimaratos M, Chambost H, Alessi MC, Baccini V. Bernard-Soulier syndrome: first human case due to a homozygous deletion of GP9 gene. Br J Haematol 2020; 188:e87-e90. [PMID: 32030720 DOI: 10.1111/bjh.16374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | - Caroline Rousset-Rouvière
- Department of Multidisciplinary Pediatrics, Pediatric Nephrology Unit, La Timone, University Hospital of Marseille, Marseille, France
| | - Cornel Popovici
- Genetic Department, La Timone, University Hospital of Marseille, Marseille, France
| | - Florentine Garaix
- Department of Multidisciplinary Pediatrics, Pediatric Nephrology Unit, La Timone, University Hospital of Marseille, Marseille, France
| | - Noémie Saut
- Hematology Laboratory, La Timone University Hospital of Marseille, Marseille, France
| | - Paul Saultier
- Department of Pediatric Hematology, La Timone Hospital, Marseille, France
| | - Michel Tsimaratos
- Department of Multidisciplinary Pediatrics, Pediatric Nephrology Unit, La Timone, University Hospital of Marseille, Marseille, France
| | - Hervé Chambost
- Department of Pediatric Hematology, La Timone Hospital, Marseille, France
| | | | | |
Collapse
|
10
|
Helias P, Lafrance W, Chalabi T, Hippomene O, Clavier D, Gaumond S, Berdou M, Saliege M, Garin B, Laruelle M, Deloumeaux J, Parrens M, Baccini V. ADULT T-CELL LEUKEMIA/LYMPHOMA: EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF A CARIBBEAN COHORT FROM GUADELOUPE. Hematol Oncol 2019. [DOI: 10.1002/hon.162_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Helias
- Hematology and Oncology Department; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| | - W.C. Lafrance
- Hematology and Oncology Department; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| | - T. Chalabi
- Hematology Laboratory; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| | - O. Hippomene
- Hematology and Oncology Department; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| | - D. Clavier
- Hematology and Oncology Department; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| | - S. Gaumond
- Pathology; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| | - M. Berdou
- Pharmacy; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| | - M. Saliege
- Pharmacy; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| | - B. Garin
- Hematology Laboratory; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| | - M. Laruelle
- Medical Oncology; Medical Center of Saint Martin; Saint Martin France
| | - J. Deloumeaux
- General Cancer Registry of Guadeloupe; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| | - M. Parrens
- Pathology; University Hospital of Bordeaux; Pessac France
| | - V. Baccini
- Hematology Laboratory; University Hospital of Guadeloupe; Pointe à Pitre/Abymes France
| |
Collapse
|
11
|
Hélias P, Lafrance W, Chalabi T, Hippomène O, Clavier D, Gaumond S, Saliège M, Berdou M, Garin B, Laruelle M, Deloumeaux J, Parrens M, Baccini V. PS1097 ADULT T-CELL LEUKEMIA/LYMPHOMA: EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF A CARIBBEAN COHORT FROM GUADELOUPE. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000562680.79625.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
12
|
Ghalloussi D, Saut N, Bernot D, Pillois X, Rameau P, Sébahoun G, Alessi MC, Raslova H, Baccini V. A new heterozygous mutation in GP1BA
gene responsible for macrothrombocytopenia. Br J Haematol 2017; 183:503-506. [DOI: 10.1111/bjh.14986] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Dorsaf Ghalloussi
- UMR1062 INSERM; Medicine Faculty; Aix Marseille University; Marseille France
| | - Noémie Saut
- Haematology laboratory; Hôpital La Timone; Assistance Publique-Hôpitaux de Marseille; Marseille France
| | - Denis Bernot
- Haematology laboratory; Hôpital La Timone; Assistance Publique-Hôpitaux de Marseille; Marseille France
| | - Xavier Pillois
- INSERM 1034; Haematology Laboratory; Centre Hospitalo-Universitaire; Bordeaux France
| | - Philippe Rameau
- PFIC, UMS AMMICA (UMS 3655 CNRS/US 23 INSERM); Gustave Roussy Cancer Campus; Villejuif France
| | - Gérard Sébahoun
- Haematology Laboratory; Hôpital Nord; Assistance Publique-Hôpitaux de Marseille; Marseille France
| | - Marie-Christine Alessi
- UMR1062 INSERM; Medicine Faculty; Aix Marseille University; Marseille France
- Centre de Référence des Pathologies Plaquettaires; Hôpital La Timone; Assistance Publique-Hôpitaux de Marseille; Marseille France
| | - Hana Raslova
- INSERM 1170; Gustave Roussy Cancer Campus; Villejuif France
| | - Véronique Baccini
- UMR1062 INSERM; Medicine Faculty; Aix Marseille University; Marseille France
- Haematology Laboratory; Hôpital Nord; Assistance Publique-Hôpitaux de Marseille; Marseille France
- Centre de Référence des Pathologies Plaquettaires; Hôpital La Timone; Assistance Publique-Hôpitaux de Marseille; Marseille France
| |
Collapse
|
13
|
Saultier P, Vidal L, Canault M, Bernot D, Falaise C, Pouymayou C, Bordet JC, Saut N, Rostan A, Baccini V, Peiretti F, Favier M, Lucca P, Deleuze JF, Olaso R, Boland A, Morange PE, Gachet C, Malergue F, Fauré S, Eckly A, Trégouët DA, Poggi M, Alessi MC. Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features. Haematologica 2017; 102:1006-1016. [PMID: 28255014 PMCID: PMC5451332 DOI: 10.3324/haematol.2016.153577] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Accepted: 02/24/2017] [Indexed: 12/20/2022] Open
Abstract
Congenital macrothrombocytopenia is a family of rare diseases, of which a significant fraction remains to be genetically characterized. To analyze cases of unexplained thrombocytopenia, 27 individuals from a patient cohort of the Bleeding and Thrombosis Exploration Center of the University Hospital of Marseille were recruited for a high-throughput gene sequencing study. This strategy led to the identification of two novel FLI1 variants (c.1010G>A and c.1033A>G) responsible for macrothrombocytopenia. The FLI1 variant carriers’ platelets exhibited a defect in aggregation induced by low-dose adenosine diphosphate (ADP), collagen and thrombin receptor-activating peptide (TRAP), a defect in adenosine triphosphate (ATP) secretion, a reduced mepacrine uptake and release and a reduced CD63 expression upon TRAP stimulation. Precise ultrastructural analysis of platelet content was performed using transmission electron microscopy and focused ion beam scanning electron microscopy. Remarkably, dense granules were nearly absent in the carriers’ platelets, presumably due to a biogenesis defect. Additionally, 25–29% of the platelets displayed giant α-granules, while a smaller proportion displayed vacuoles (7–9%) and autophagosome-like structures (0–3%). In vitro study of megakaryocytes derived from circulating CD34+ cells of the carriers revealed a maturation defect and reduced proplatelet formation potential. The study of the FLI1 variants revealed a significant reduction in protein nuclear accumulation and transcriptional activity properties. Intraplatelet flow cytometry efficiently detected the biomarker MYH10 in FLI1 variant carriers. Overall, this study provides new insights into the phenotype, pathophysiology and diagnosis of FLI1 variant-associated thrombocytopenia.
Collapse
Affiliation(s)
- Paul Saultier
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France
| | - Léa Vidal
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France
| | | | - Denis Bernot
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France
| | - Céline Falaise
- APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| | - Catherine Pouymayou
- APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| | | | - Noémie Saut
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France.,APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| | - Agathe Rostan
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France.,APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| | - Véronique Baccini
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France.,APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| | | | - Marie Favier
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France
| | - Pauline Lucca
- ICAN Institute for Cardiometabolism and Nutrition, Paris, France.,Inserm, UMR_S 1166, Team Genomics and Pathophysiology of Cardiovascular Diseases, Paris, France.,Sorbonne Universités, Université Pierre et Marie Curie (UPMC Univ Paris 06), UMR_S 1166, France
| | | | - Robert Olaso
- Centre National de Génotypage, Institut de Génomique, CEA, Evry, France
| | - Anne Boland
- Centre National de Génotypage, Institut de Génomique, CEA, Evry, France
| | - Pierre Emmanuel Morange
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France.,APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| | - Christian Gachet
- UMR_S949 INSERM, Strasbourg, France.,Etablissement Français du Sang (EFS)-Alsace, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), France.,Université de Strasbourg, Marseille, France
| | - Fabrice Malergue
- Beckman Coulter Immunotech, Life Sciences Global Assay and Applications Development, Marseille, France
| | - Sixtine Fauré
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France
| | - Anita Eckly
- UMR_S949 INSERM, Strasbourg, France.,Etablissement Français du Sang (EFS)-Alsace, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), France.,Université de Strasbourg, Marseille, France
| | - David-Alexandre Trégouët
- ICAN Institute for Cardiometabolism and Nutrition, Paris, France.,Inserm, UMR_S 1166, Team Genomics and Pathophysiology of Cardiovascular Diseases, Paris, France.,Sorbonne Universités, Université Pierre et Marie Curie (UPMC Univ Paris 06), UMR_S 1166, France
| | - Marjorie Poggi
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France
| | - Marie-Christine Alessi
- Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France.,APHM, CHU Timone, French Reference Center on Inherited Platelet Disorders, Marseille, France
| |
Collapse
|
14
|
Bonello L, Laine M, Baccini V, Frere C. Parameters of complete blood count do not predict on-treatment platelet reactivity in acute coronary syndrome patients. Thromb Res 2017; 152:38-40. [PMID: 28219844 DOI: 10.1016/j.thromres.2017.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Revised: 02/05/2017] [Accepted: 02/10/2017] [Indexed: 10/20/2022]
Affiliation(s)
- Laurent Bonello
- Assistance Publique-Hôpitaux de Marseille, Department of Cardiology, Hôpital Nord, Marseille, France; Mediterranean Academic association for Research and Studies in Cardiology (MARS Cardio), Marseille, France; Aix-Marseille University, INSERM, UMRS 1076, Marseille, France.
| | - Marc Laine
- Assistance Publique-Hôpitaux de Marseille, Department of Cardiology, Hôpital Nord, Marseille, France; Mediterranean Academic association for Research and Studies in Cardiology (MARS Cardio), Marseille, France; Aix-Marseille University, INSERM, UMRS 1076, Marseille, France
| | - Véronique Baccini
- Assistance Publique-Hôpitaux de Marseille, Department of Haematology, Marseille, France; Aix-Marseille University, INSERM, UMRS 1062, Marseille, France
| | - Corinne Frere
- Assistance Publique-Hôpitaux de Marseille, Department of Haematology, Marseille, France; Aix-Marseille University, INSERM, UMRS 1076, Marseille, France
| |
Collapse
|
15
|
Manchev VT, Bouzid H, Antony-Debré I, Leite B, Meurice G, Droin N, Prebet T, Costello RT, Vainchenker W, Plo I, Diop M, Macintyre E, Asnafi V, Favier R, Baccini V, Raslova H. Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0. J Cell Mol Med 2016; 21:1237-1242. [PMID: 27997762 PMCID: PMC5431233 DOI: 10.1111/jcmm.13051] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2016] [Accepted: 10/30/2016] [Indexed: 12/03/2022] Open
Abstract
Familial platelet disorder with predisposition to acute myeloid leukaemia (FPD/AML) is characterized by germline RUNX1 mutations, thrombocytopaenia, platelet dysfunction and a risk of developing acute myeloid and in rare cases lymphoid T leukaemia. Here, we focus on a case of a man with a familial history of RUNX1R174Q mutation who developed at the age of 42 years a T2‐ALL and, 2 years after remission, an AML‐M0. Both AML‐M0 and T2‐ALL blast populations demonstrated a loss of 1p36.32‐23 and 17q11.2 regions as well as other small deletions, clonal rearrangements of both TCRγ and TCRδ and a presence of 18 variants at a frequency of more than 40%. Additional variants were identified only in T2‐ALL or in AML‐M0 evoking the existence of a common original clone, which gave rise to subclonal populations. Next generation sequencing (NGS) performed on peripheral blood‐derived CD34+ cells 5 years prior to T2‐ALL development revealed only the missense TET2P1962T mutation at a frequency of 1%, which increases to more than 40% in fully transformed leukaemic T2‐ALL and AML‐M0 clones. This result suggests that TET2P1962T mutation in association with germline RUNX1R174Q mutation leads to amplification of a haematopoietic clone susceptible to acquire other transforming alterations.
Collapse
Affiliation(s)
- Vladimir T Manchev
- INSERM UMR 1170, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Villejuif, France.,Université Paris Diderot, Paris, France
| | - Hind Bouzid
- INSERM UMR 1170, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Villejuif, France.,Université Paris Diderot, Paris, France
| | - Iléana Antony-Debré
- INSERM UMR 1170, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Villejuif, France
| | - Betty Leite
- Gustave Roussy, Université Paris-Saclay, Genomic Platform UMS AMMICA, Villejuif, France
| | - Guillaume Meurice
- Gustave Roussy, Université Paris-Saclay, Bioinformatic Core Facility UMS AMMICA, Villejuif, France
| | - Nathalie Droin
- INSERM UMR 1170, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Villejuif, France.,Gustave Roussy, Université Paris-Saclay, Genomic Platform UMS AMMICA, Villejuif, France
| | - Thomas Prebet
- Faculté de Médecine, Aix-Marseille Université, Marseille, France.,Département d'Hématologie, Institut Paoli-Calmettes, Marseille, France
| | - Régis T Costello
- Assistance Publique-Hôpitaux de Marseille, Hôpital de La Conception, Service d'Hématologie et Thérapie Cellulaire, Faculté de Médecine, Aix-Marseille Université, INSERM UMR 1090 TAGC, Marseille, France
| | - William Vainchenker
- INSERM UMR 1170, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Villejuif, France
| | - Isabelle Plo
- INSERM UMR 1170, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Villejuif, France
| | - M'boyba Diop
- INSERM UMR 1170, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Villejuif, France.,Gustave Roussy, Université Paris-Saclay, Bioinformatic Core Facility UMS AMMICA, Villejuif, France
| | - Elizabeth Macintyre
- Hematology and INSERM U1151, Institut Necker-Enfants Malades, Université Sorbonne Paris Cité, Descartes and Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Vahid Asnafi
- Hematology and INSERM U1151, Institut Necker-Enfants Malades, Université Sorbonne Paris Cité, Descartes and Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Rémi Favier
- INSERM UMR 1170, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Villejuif, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau, Service d'Hématologie biologique, Paris, France
| | - Véronique Baccini
- Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Laboratoire d'Hématologie, Faculté de Médecine, Aix-Marseille Université, INSERM UMR_S 1062, Marseille, France
| | - Hana Raslova
- INSERM UMR 1170, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Villejuif, France
| |
Collapse
|
16
|
Abstract
Inherited thrombocytopenias are rare, heterogenous and probably under-diagnosed because often classified as autoimmune thrombocytopenia. About 20 genes were described responsible for these thrombocytopenias. Precise diagnosis is necessary because the prognosis is different and some of them can evolve into hemopathies. First of all, it is important to gather a body of evidence to orientate towards an inherited cause: presence of the thrombocytopenia since childhood and of other family cases is a strong argument. Secondly, it is difficult to target the genetic investigations that settle the precise diagnosis. Genetic variants responsible for inherited thrombocytopenias affect different stage during megakaryocytopoiesis and cause thrombocytopenias with distinct characteristics. Presence of extra-hematological features, platelets' size measurement and evaluation of bone marrow megakaryocyte morphology when it is possible allow a primary orientation. We propose a diagnostic approach considering extra-hematological features, mode of inheritance, morphology, molecular and functional platelets' studies and bone marrow megakaryocyte morphology in order to better target genetic study. Nevertheless, despite this approach, some inherited thrombocytopenias remain still unexplained and could benefit from new methods of new generation sequencing in the future.
Collapse
Affiliation(s)
- V Baccini
- Laboratoire d'hématologie, hôpital Nord, CHU de Marseille, chemin des Bourrelly, 13015 Marseille, France; Centre de référence des pathologies plaquettaires (CRPP), CHU Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France.
| | - M C Alessi
- Laboratoire d'hématologie, hôpital Nord, CHU de Marseille, chemin des Bourrelly, 13015 Marseille, France; Centre de référence des pathologies plaquettaires (CRPP), CHU Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France
| |
Collapse
|
17
|
Granel B, Baccini V, Serratrice J, Pouymayou K, Schlegel N, Alessi MC, Weiller PJ. Une nouvelle mutation du gène MYH9 associée au syndrome de May-Hegglin. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Letestu R, Marzac C, Audat F, Belhocine R, Tondeur S, Baccini V, Garçon L, Cortivo LD, Perrot JY, Lefrère F, Valensi F, Ajchenbaum-Cymbalista F. Use of hematopoietic progenitor cell count on the Sysmex XE-2100 for peripheral blood stem cell harvest monitoring. Leuk Lymphoma 2009; 48:89-96. [PMID: 17327950 DOI: 10.1080/10428190600886149] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Successful peripheral blood stem cell (PBSC) collection depends on the timing of apheresis based on CD34+ cell enumeration. Because this analysis is expensive and induces organization difficulties, we evaluated hematopoietic progenitor cell (HPC) quantification on the Sysmex XE-2100 as a surrogate analysis. We tested 157 blood samples for CD34+ cells and HPC counts. We found a good linear correlation between HPC and CD34+ and determined simple rules allowing to use HPC count in daily practice. We set a positive cut-off >30 HPC/mm(3) for allowing PBSC harvest and a negative cut-off at 0 HPC/mm(3) for which collection should be delayed. These two situations accounted for 62% of cases and CD34+ cell count by flow cytometry confirmed HPC result in 95% of cases. Between 0 and 30 HPC/mm3, CD34+ enumeration is required for decision-making. We conclude that HPC count may be a useful surrogate for CD34+ enumeration in PBSC harvest monitoring.
Collapse
Affiliation(s)
- Rémi Letestu
- Laboratoire Central d'Hématologie, Hôpital Necker Enfants Malades, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
|
20
|
Raslova H, Baccini V, Loussaief L, Comba B, Larghero J, Debili N, Vainchenker W. Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood 2006; 107:2303-10. [PMID: 16282343 DOI: 10.1182/blood-2005-07-3005] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
AbstractA major determinant in platelet production is the megakaryocyte (MK) size that is regulated both by ploidization and the increase in cytoplasmic volume at the end of maturation. Here we investigated the involvement of the mammalian target of rapamycin (mTOR) pathway in the regulation of megakaryopoiesis. We show that phosphorylation of mTOR, p70S6K1, and 4E-BP1 was diminished in thrombopoietin-cultured human MKs after rapamycin treatment. Rapamycin induced an inhibition in the G1/S transition and a decrease in the mean MK ploidy via a diminution of p21 and cyclin D3 occurring at a transcriptional level. Both cycling (2N/4N) and polyploid (8N/16N) MKs were reduced in size, with a size reduction slightly more pronounced in mature polyploid MKs than in immature ones. Rapamycin also induced a delay in the expression of MK markers and prevented the generation of proplatelet MKs. Additional experiments performed in vitro with MKs from mutant mice showed that the decrease in mean ploidy level and the delay in MK differentiation in the presence of rapamycin were less pronounced in CdknIa (p21)–/– MKs than in CdknIa (p21)+/+ MKs. These findings indicate that the mTOR pathway plays an important role during megakaryopoiesis by regulating ploidy, cell size, and maturation, in part by regulating p21 and cyclin D3.
Collapse
Affiliation(s)
- Hana Raslova
- INSERM U790, Institut Gustave Roussy PR1, Villejuif, France.
| | | | | | | | | | | | | |
Collapse
|
21
|
Baccini V, Roy L, Vitrat N, Chagraoui H, Sabri S, Le Couedic JP, Debili N, Wendling F, Vainchenker W. Role of p21(Cip1/Waf1) in cell-cycle exit of endomitotic megakaryocytes. Blood 2001; 98:3274-82. [PMID: 11719364 DOI: 10.1182/blood.v98.12.3274] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The cyclin-dependent kinase inhibitor p21(Waf-1/Cip-1) is expressed at high level during megakaryocyte differentiation, but its precise function remains unknown. In this study, it is confirmed that p21 was expressed at a high level in hypoploid (2N and 4N) and polyploid (at least 8N) human megakaryocytes derived from CD34(+) cells. A high expression of p27(Kip1), p16, cyclin E, and cyclin D3 was also found in both populations associated with a hypophosphorylated form of retinoblastoma protein, suggesting that the majority of hypoploid and polyploid megakaryocytes are G(1)-arrested cells. As human megakaryocytes grown in vitro present a defect in their polyploidization, the study switched to the murine model. The modal ploidy of megakaryocytes derived from lineage-negative cells was 32N, and an elevated expression of p21 was found in high-ploidy megakaryocytes. In addition, p21 and p27 were coexpressed in the majority of mature polyploid megakaryocytes. The p21 was detected by immunofluorescence in megakaryocytes derived from p53(-/-) mice, demonstrating a p53-independent regulation during megakaryocyte differentiation. Megakaryocytopoiesis of p21(-/-) mice was subsequently studied. No marked abnormality in the ploidy of primary or cultured megakaryocytes was detected. Overexpression of p21 in p21(-/-) or normal murine megakaryocytes and in human megakaryocytes showed in all these cases a marked inhibition in megakaryocyte polyploidization. In conclusion, while a reciprocal relation is observed between p21 levels in megakaryocytes and the cycling state of the cells, p21 is not essential for the determination of the ploidy profile in normal megakaryocytes in vivo. However, high levels of its expression in cultured megakaryocytes arrest the endomitotic cell cycle.
Collapse
Affiliation(s)
- V Baccini
- INSERM U 362, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|